Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

Benzinga Newsdesk www.benzinga.com Neutral 53.5%

Neg 0% Neu 53.5% Pos 0%

Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.